RPMA.01.02.00-14-5721/16

Between 2016 and 2022, NanoSanguis implemented a project co-financed by the European Funds entitled “Red Blood Cell Substitute.”

The aim of the project was to develop a safe red blood cell substitute, also known as “artificial blood,” for therapeutic use in humans.

As part of the project, a prototype of a blood substitute was developed in the form of a suspension of microparticles with a liquid core containing a synthetic oxygen carrier, stabilized by proprietary ionic fluorosurfactants. This substitute was tested in pilot studies on a small animal model (rats) and a large animal model (pigs).

Total project value: PLN 2,915,667.53
EU co-financing: PLN 1,677,007.83